ArticleEndocrine2025
The blood transcriptome of the human congenital generalized lipodystrophy.
Article in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCongenital generalized lipodystrophy (CGL), also known as Berardinelli-Seip syndrome, is a recessive genetic disease. Affected individuals present musculoskeletal abnormalities, insulin resistance, hepatic steatosis, and may develop cardiomyopathy and mental retardation The mechanism linking AGPAT2 (for CGL1) and BSCL2 (for CGL2) mutations to the syndrome has yet to be fully understood.
methodsHere, we analyzed blood cell transcriptomes from individuals with CGL1 (n = 3), CGL2 (n = 12), unaffected BSCL2 heterozygotes (HET, n = 8), and healthy individuals (CTRL, n = 3). Study participants were also evaluated by densitometry (GE Lunar DPX), in addition to biochemical panel and pro-inflammatory cytokines measured in serum.
resultsThe gene expression profile of CGL1 was similar to CTRL, a result likely due to the compensatory activity of other AGPAT isoforms. CGL2 had 283 differentially expressed genes (DEGs), most enriched for neurodegenerative- and mitochondria-related genes. There was a negative correlation between the top1 gene, NUAK2, and fat mass (rho = -0.55, p = 0.01). The HET group had 105 DEGs, with OLR1, an atherogenic gene, as the most significant (P
conclusionBoth CGL2 individuals and their unaffected relatives had abnormal gene expression pattern. Further epidemiological studies should seek to assess cardiovascular risk in heterozygote individuals.
Indexed as
Identifiers
40360872What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.